» Articles » PMID: 38232988

Pulmonary Veno-occlusive Disease: Illustrative Cases and Literature Review

Overview
Journal Eur Respir Rev
Specialty Pulmonary Medicine
Date 2024 Jan 17
PMID 38232988
Authors
Affiliations
Soon will be listed here.
Abstract

Pulmonary veno-occlusive disease (PVOD), also known as "pulmonary arterial hypertension (PAH) with overt features of venous/capillary involvement", is a rare cause of PAH characterised by substantial small pulmonary vein and capillary involvement, leading to increased pulmonary vascular resistance and right ventricular failure. Environmental risk factors have been associated with the development of PVOD, such as occupational exposure to organic solvents and chemotherapy, notably mitomycin. PVOD may also be associated with a mutation in the gene in heritable forms of disease. Distinguishing PVOD from PAH is critical for guiding appropriate management. Chest computed tomography typically displays interlobular septal thickening, ground-glass opacities and mediastinal lymphadenopathy. Life-threatening pulmonary oedema is a complication of pulmonary vasodilator therapy that can occur with any class of PAH drugs in PVOD. Early referral to a lung transplant centre is essential due to the poor response to therapy when compared with other forms of PAH. Histopathological analysis of lung explants reveals microvascular remodelling with typical fibrous veno-occlusive lesions. This review covers the main features distinguishing PVOD from PAH and two clinical cases that illustrate the challenges of PVOD management.

Citing Articles

Posterior Spinal Cord Infarction Complicating a Bronchial Arterial Embolization.

Barbosa Mateus D, Dionisio A, Mendes T, Araujo A, Goncalves Pereira J Cureus. 2024; 16(11):e73594.

PMID: 39677259 PMC: 11639612. DOI: 10.7759/cureus.73594.


Definition, classification and diagnosis of pulmonary hypertension.

Kovacs G, Bartolome S, Denton C, Gatzoulis M, Gu S, Khanna D Eur Respir J. 2024; 64(4).

PMID: 39209475 PMC: 11533989. DOI: 10.1183/13993003.01324-2024.


From the microscopic to the macroscopic: clinical-radiological-pathological correlation in pulmonary hypertension.

Condliffe R, Dorfmuller P, Gopalan D, Sitbon O, Vonk Noordegraaf A Eur Respir Rev. 2023; 32(170).

PMID: 38123237 PMC: 10731445. DOI: 10.1183/16000617.0237-2023.

References
1.
Laveneziana P, Montani D, Dorfmuller P, Girerd B, Sitbon O, Jais X . Mechanisms of exertional dyspnoea in pulmonary veno-occlusive disease with EIF2AK4 mutations. Eur Respir J. 2014; 44(4):1069-72. DOI: 10.1183/09031936.00088914. View

2.
Benza R, Miller D, Barst R, Badesch D, Frost A, McGoon M . An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest. 2012; 142(2):448-456. DOI: 10.1378/chest.11-1460. View

3.
Montani D, Savale L, Natali D, Jais X, Herve P, Garcia G . Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. Eur Heart J. 2010; 31(15):1898-907. DOI: 10.1093/eurheartj/ehq170. View

4.
Seferian A, Helal B, Jais X, Girerd B, Price L, Gunther S . Ventilation/perfusion lung scan in pulmonary veno-occlusive disease. Eur Respir J. 2011; 40(1):75-83. DOI: 10.1183/09031936.00097911. View

5.
Johnson S, Patsios D, Hwang D, Granton J . Pulmonary veno-occlusive disease and scleroderma associated pulmonary hypertension. J Rheumatol. 2006; 33(11):2347-50. View